Cost-effectiveness of screening for common cancers

Cancer and Metastasis Reviews

Volumn 16, Issue 3-4, 1997, Pages 281-294

  Wagner, Judith L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer; Cervix; Colon; Cost effectiveness; Costs; Rectum; Screening

Indexed keywords

CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; OCCULT BLOOD TEST; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0030714551     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1005800227359     Document Type: Review

References (70)

1. US Congress Office of Technology Assessment. The implications of cost-effectiveness analysis of medical technology. US Government Printing Office. Washington, DC; OTA-H: 126, 1980
2. US Congress, Office of Technology Assessment. Identifying health technologies that work: Searching for evidence, US Government Printing Office, Washington, DC: 1994
3. Hlatky MA: Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 336 (2): 92, 1997
4. Mark DB, Hlatky MA, Cliff RM et al.: Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332 (12): 1418-1424, 1995
5. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practices in the diabetes control and complications trial. JAMA 276 (17): 1409-1415, 1996
6. Owens DK, Sanders GD, Hlatky MA: Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 126 (1): 1997
7. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC: For the panel on cost-effectiveness in health and medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 276 (14): 1172-1177, 1996
8. Kane RL, Kane RA, Arnold SB: Prevention in the elderly: Risk factors. Health Serv Res 19 (6,II): 946-1006, 1985
9. US Department of Health and Human Services, Public Health Service. Surgeon General's workshop: Health promotion and aging, proceedings. Washington, DC: US Government Printing Office, 1988
10. Sackett DL, Holland WW: Controversy in the detection of disease. Lancet 2: 357-359, 1975
11. US Congress, Office of Technology Assessment. A review of selected federal vaccine and immunization policies: Based on case studies of pneumococcal vaccine, US Government Printing Office. Washington, DC: 1979
12. Eddy DM: Screening for Cancer: Theory, analysis, and design, Prentice-Hall, Inc.: Englewood Cliffs, NJ: 1980
13. Eddy DM: Screening for cervical cancer. Ann Intern Med 113 (3): 214-226, 1990
14. Eddy DM: Screening for colorectal cancer. Ann Intern Med 113: 373-384 1990
15. Eddy DM, Hasselblad V, McGivney W, Hendee W: The value of mammography screening in women under age 50 years. JAMA 259 (10): 1512-1519, 1988
16. Eddy DM, Nugent FW, Eddy JF, Coller J, Gilbertsen V, Gottlieb LS, Rice R, Sherlock P, Winawer S: Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology 92 (3): 682-692, 1987
17. Eddy DM: Breast cancer screening for medicare beneficiaries: Effectiveness, costs to medicare and medical resources required, US Congress, Office of Technology Assessment. Washington, DC, 1987
18. Drummond M, O'Brien B: Economic analysis alongside clinical trials: Practical considerations. The economic workgroup. J of Rheumat 22 (7): 1418-1419, 1995
19. O'Brien BJ, Drummond MF, Labelle RJ, Willian A: In search of power and significance issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 32 (2): 150-163, 1994
20. Schulman KA, Glick HA, Yabroff KR, Eisenberg JM: Introduction to clinical economics: Assessment of cancer therapies. J Natl Cancer Inst Monographs 19: 1-9, 1995
21. Weeks JC: Special issues that arise in applying techniques of economic analysis to evaluation of cancer therapies. J Natl Cancer Inst Monographs 19: 11-12, 1995
22. Mandel JS, Bond JH, Church TR et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl Med 328: 1365-1371, 1993
23. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477, 1996
24. Kronberg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348: 1467-1471, 1996
25. Law AM, Kelton WD: Simulation Modeling and Analysis. McGraw-Hill, Inc., New York, NY, 1991
26. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in Health and Medicine, Oxford University Press, Inc., New York, NY, 1996
27. Hall J, Gerard K, Salkeld G et al.: A cost utility analysis of mammography screening in Australia. Soc Sci Med 34 (9): 993-1004, 1992
28. Health Care Financing Administration, Bureau of Data Management and Strategy, Persons served under medicare and program payments, by type of high-cost user: Calendar year 1994. Health Care Financing Review, 1996 Statistical Supplement, p 220
29. Cook GA, Draper GJ: Trends in cervical cancer and carcinoma in situ in Great Britain. Br J Cancer 50: 367-375, 1984
30. Dickinson L, Mussey ME, Soule EH et al.: Evaluation of the effectiveness of cytologic screening for cervical cancer: I. Mayo Clin Proc 42: 534-538, 1972
31. Fidler HK, Boyes DA, Worth AJ: Cervical cancer detection in British Columbia. J Obstet Gynaecol Brit Cwlth 75: 392-404, 1968
32. Hakama M: Trends in the incidence of cervical cancer in the Nordic Countries. In: Magnus K (ed) Trends in Cancer Incidence: Cases and Practical Implications. Washington, DC: Hemisphere Publishing Corporation, 1982
33. Johannesson G, Geirsson G, Day N et al.: The effect of mass screening in Iceland, 1965-1974, on the incidence and mortality of cervical carcinoma. Int J Cancer 21: 418-425, 1978
34. Kim K, Rigel R, Parick D et al.: The changing trends of uterine cancer and cytology: A study of morbidity and mortality trends over a twenty-year period. Cancer 42: 2439-2449, 1978
35. Miller AB, Lindsay J, Hill GB: Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 17: 602-612, 1976
36. Miller AB, Visentin T, Howe GR: The effects of hysterectomies and screening on mortality of cancer of the uterus in Canada. Int J Cancer 27: 651-657, 1981
37. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute & National Cancer Advisory Board, 1987 Annual Cancer Statistics Review, US DHHS Publication, National Cancer Institute. Bethesda, MD, 1988
38. Pollack ES: Cancer incidence trends in the United States: Some methodological problems. In: Magnus K (ed) Trends in Cancer Incidence. Washington, DC: Hemisphere Publishing Corporation, 1982
39. Boyes DA: The value of a pap smear program and suggestions for its implementation. Cancer 48: 613-621, 1981
40. Anderson GH, Boyes DA, Benedet JL et al.: Organization and results of the cervical cytology screening programme in British Columbia. Br Med J 296: 975-978, 1988
41. Aristizabal N, Cuello C, Corrca P et al.: The impact of vaginal cytology on cervical cancer risks in Cali, Columbia. Int J Cancer 34: 5-9, 1984
42. Berrino F, Gatta G, d'Alto M et al.: Efficacy of screening in preventing invasive cervical cancer: A case-control study in Milan, Italy. In: Hakama M, Miller AB, Day NE (eds) Screening for Cancer of the Uterine Cervix. Lyon, France: IARC Scientific Publications No. 76, 1986
43. Clarke E, Anderson T: Does screening by 'Pap' smears help prevent cervical cancer?' Lancet 2 (813): 1-4, 1979
44. Koopmanschap MA, van Oortmarssen GJ, van Agt HM, van Ballegooijen M, Habbema JDF, Lubbe JThN: Cervical-cancer screening: Attendance and cost-effectiveness. Int J Cancer 45 (3): 410-415, 1990
45. Habbema JDF, Lubbe JThN, van Oortmarssen GJ, van der Maas PJ: A simulation approach to cost-effectiveness and cost-benefit calculations of screening for the early detection of disease. Eur J of Operational Res 29 (2): 159-166, 1987
46. Habbema JDF, van Oortmarssen GJ, Lubbe JThN, van der Maas PJ: The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed 20 (1): 79-93, 1984
47. van Ballegooijen M, Habbema JDF, van Oortmarssen GJ, Koopmanschap MA, Lubbe JThN, van Agt HM: Preventive pap-smears: Balancing costs, risks and benefits. Br J Cancer 65 (6): 930-933, 1992
48. van Oortmarssen GJ, Boer R, Habbema JDF: Modelling issues in cancer screening. Stat Methods Med Res 4 (1): 33-54, 1995
49. van Oortmarssen GJ, Habbema JDF, Lubbe JThN, van der Maas PJ: A model-based analysis of the HIP project for breast cancer screening. Int J Cancer 46: 207-213, 1990
50. US Congress, Office of technology assessment. The costs and effectiveness of screening for cervical cancer in elderly women. Background paper. US Government Printing Office. Washington, DC, 1990
51. Fahs MC, Mandelblatt J, Schechter C, Muller C: Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 117 (6): 520-527, 1992
52. Fink DJ: Change in American Cancer Society checkup guidelines for detection of cervical cancer. Cancer 38: 127-128, 1988
53. Canadian Task Force on the Periodic Health Examination: The periodic health examination. Can Med Assoc J 121 (9): 1193-1254, 1979
54. Kiviat NB, Koutsky LA: Do occurring current cervical cancer control strategies still make sense? J Natl Cancer Inst 88 (6): 317-318, 1996
55. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann A, De Rouen TA, Galloway DA, Vernon D, Kiviat NB: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 (18): 1272-1278, 1992
56. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J: Human papillomavirus testing in primary cervical screening. Lancet 345 (8964): 1533-1536, 1995
57. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM: Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265 (4): 472-477, 1991
58. US Congress Congressional Budget Office. CBO's Colorectal cancer screening model (letter from June E. O'Neill to Congressman Cliff Stearns, US House of Representatives). June 8, 1996
59. US Congress, Office of Technology Assessment. Cost-effectiveness of colorectal cancer screening in the elderly. US Government Printing Office. Washington, DC, 1990
60. US Congress, Office of Technology Assessment Cost-effectiveness of colorectal cancer screening average-risk adults, US Government Printing Office. Washington, DC, 1995
61. Wagner JL, Herdman RC, Wadhwa S: Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 115 (10): 807-817, 1991
62. Wagner JL, Tunis S, Brown M, Ching A, Almeida R: Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young GP, Rozen P, Levin B (eds) Prevention and Early Detection of Colorectal Cancer. Philadelphia: WB Saunders Company Ltd, pp 321-356, 1996
63. Bang KM, Tillett S, Hoar S et al.: Sensitivity of fecal hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening. J Occupational Med 28 (8): 709-713, 1986
64. Demers R, Stawick L, Demers P: Relative sensitivity of the fecal occult blood tests and flexible sigmoidscopy in detecting polyps. Prev Med 14: 55-62, 1985
65. Allison JE, Feldman F: Cost benefits of hemoccult screening for colorectal carcinoma. Dig Dis Sci 30 (9): 860-865, 1985
66. Barry MJ, Mulley AG, Richter JM: The effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer. Gastroenterology 93: 301-310, 1987
67. England WL, Halls JL, Hunt VB: Strategies for screening colorectal carcinoma. Med Decis Making 9: 3-13, 1989
68. Joseph AM, Crowson TW, Rick EC: Cost effectiveness of hemoquant versus hemoccult for colorectal cancer screening. J of Gen Internal Med 3: 132-138, 1988
69. Lieberman DA: Cost-effectiveness model for colon cancer screening. Gastroenterology 109: 1781-1790, 1995
70. Shimbo T, Glick HA, Eisenberg JM: Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Intl J of Tech Assess Hlth Care 10 (3): 359-375, 1994